These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34877660)

  • 1. Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population.
    Williams ML; Kannankeril PJ; Breeyear JH; Edwards TL; Van Driest SL; Choi L
    Clin Pharmacol Ther; 2022 Apr; 111(4):896-908. PubMed ID: 34877660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery.
    Zhang W; Yuan JJ; Kan QC; Zhang LR; Chang YZ; Wang ZY; Li ZS
    Eur J Anaesthesiol; 2011 Apr; 28(4):245-50. PubMed ID: 21513075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
    Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
    J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children.
    Hagos FT; Horvat CM; Au AK; Conley YP; Li L; Poloyac SM; Kochanek PM; Clark RSB; Empey PE
    Clin Pharmacokinet; 2019 Dec; 58(12):1567-1576. PubMed ID: 31168770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
    Cvetković M; Zivković M; Bundalo M; Gojković I; Spasojević-Dimitrijeva B; Stanković A; Kostić M
    Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
    Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.
    Monostory K; Tóth K; Kiss Á; Háfra E; Csikány N; Paulik J; Sárváry E; Kóbori L
    Br J Clin Pharmacol; 2015 Dec; 80(6):1429-37. PubMed ID: 26271661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
.
    Huang Y; Wen G; Lu Y; Wen J; Ji Y; Xing X; Li Y; Wen J; Yuan H
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):109-118. PubMed ID: 27841150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function.
    Fohner AE; Dalton R; Skagen K; Jackson K; Claw KG; Hopkins SE; Robinson R; Khan BA; Prasad B; Schuetz EG; Nickerson DA; Thornton TA; Dillard DA; Boyer BB; Thummel KE; Woodahl EL
    Clin Transl Sci; 2021 Jul; 14(4):1292-1302. PubMed ID: 33503331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of CYP3A4*1G and CYP3A5*3 With the 1-year Outcome of Acute Ischemic Stroke in the Han Chinese Population.
    Li S; Shi CH; Liu XJ; Li YS; Li SH; Song B; Xu YM
    J Stroke Cerebrovasc Dis; 2019 Jul; 28(7):1860-1865. PubMed ID: 31064695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
    Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
    Zhou LY; Zuo XC; Chen K; Wang JL; Chen QJ; Zhou YN; Yuan H; Ma Y; Zhu LJ; Peng YX; Ming YZ
    J Clin Pharm Ther; 2016 Jun; 41(3):341-7. PubMed ID: 27149910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A4 * 1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients.
    Yuan JJ; Hou JK; Zhang W; Chang YZ; Li ZS; Wang ZY; Du YY; Ma XJ; Zhang LR; Kan QC; Candiotti KA
    Pharmacology; 2015; 96(1-2):55-60. PubMed ID: 26088794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
    Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
    Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.
    Kitzmiller JP; Luzum JA; Baldassarre D; Krauss RM; Medina MW
    Pharmacogenet Genomics; 2014 Oct; 24(10):486-91. PubMed ID: 25051018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
    Żochowska D; Wyzgał J; Pączek L
    Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.